Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Arrowhead Pharmaceuticals, Inc.”

89 pharma patents match "Arrowhead Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 89
Index total 30,257
Page 2 / 4

Quick answer

This filtered view shows 89 pharmaceutical patents matching "Arrowhead Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

89 results for “Arrowhead Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11261444

    Organic compositions to treat EPAS1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  2. US 11214801

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  3. US 11214802

    RNAi agents for inhibiting expression of alpha-ENaC and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  4. US 11208662

    RNAi inhibition of alpha-ENaC expression

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  5. US 11203756

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  6. US 11180529

    Alpha-v beta-6 integrin ligands and uses thereof

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  7. US 11174481

    Targeting ligands

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  8. US 11091761

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted

  9. US 11078227

    5′-cyclo-phosphonate modified nucleotides

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  10. US 11066667

    Organic compositions to treat APOC3-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  11. US 10995335

    RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

  12. US 10927373

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  13. US 10858658

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted

  14. US 10806750

    RNAi therapy for hepatitis B virus infection

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted

  15. US 10780108

    RNAi agents for Hepatitis B virus infection

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  16. US 10619160

    Compositions and methods for inhibiting expression of RRM2 genes

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

  17. US 10597657

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted

  18. US 10590416

    RNAi agents for inhibiting expression of alpha-ENaC and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 17, 2020 · Expires Mar 12, 2040

    granted

  19. US 10550391

    Organic compositions to treat beta-ENaC-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted

  20. US 10544418

    RNAi inhibition of alpha-ENaC expression

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted

  21. US 10538765

    Organic compositions to treat EPAS1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted

  22. US 10450565

    Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  23. US 10329563

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  24. US 10316316

    Compositions for targeted delivery of siRNA

    Arrowhead Pharmaceuticals, Inc. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.